Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 6 | 10 |
| List of Tables | 10 | 3 |
| List of Figures | 13 | 3 |
| Pain Management Therapeutics Market to 2019 - Introduction | 16 | 1 |
| Pain Management Therapeutics Market to 2019 - Market Overview | 17 | 20 |
| Introduction | 17 | 1 |
| World Health Organization Pain Ladder | 18 | 1 |
| Risk Evaluation and Mitigation Strategy | 19 | 1 |
| Revenue | 20 | 1 |
| Major Marketed Pain Management Drugs | 21 | 1 |
| Abstral (fentanyl citrate) | 21 | 1 |
| Overview | 21 | 1 |
| Mechanism of Action | 21 | 1 |
| Safety | 21 | 1 |
| Efficacy | 21 | 1 |
| Celebrex (celecoxib) | 22 | 1 |
| Overview | 22 | 1 |
| Mechanism of Action | 22 | 1 |
| Efficacy | 22 | 1 |
| Safety | 22 | 1 |
| Cymbalta (duloxetine) | 23 | 1 |
| Overview | 23 | 1 |
| Mechanism of Action | 23 | 1 |
| Efficacy | 23 | 1 |
| Safety | 23 | 1 |
| Exparel (Bupivacaine ER) | 24 | 1 |
| Overview | 24 | 1 |
| Mechanism of Action | 24 | 1 |
| Safety | 24 | 1 |
| Efficacy | 24 | 1 |
| Lidoderm (lidocaine patch) | 25 | 1 |
| Overview | 25 | 1 |
| Mechanism of Action | 25 | 1 |
| Safety | 25 | 1 |
| Efficacy | 25 | 1 |
| Lyrica (pregabalin) | 26 | 1 |
| Overview | 26 | 1 |
| Mechanism of Action | 26 | 1 |
| Efficacy | 26 | 1 |
| Safety | 26 | 1 |
| Nucynta ER (tapentadol ER) | 27 | 1 |
| Overview | 27 | 1 |
| Mechanism of Action | 27 | 1 |
| Safety | 27 | 1 |
| Efficacy | 27 | 1 |
| Qutenza (capsaicin) | 28 | 1 |
| Overview | 28 | 1 |
| Mechanism of Action | 28 | 1 |
| Safety | 28 | 1 |
| Efficacy | 28 | 1 |
| Savella (milnacipran hydrochloride) | 29 | 1 |
| Overview | 29 | 1 |
| Mechanism of Action | 29 | 1 |
| Safety | 29 | 1 |
| Efficacy | 29 | 1 |
| Vimovo (esomeprazole magnesium + naproxen) | 30 | 1 |
| Overview | 30 | 1 |
| Mechanism of Action | 30 | 1 |
| Safety | 30 | 1 |
| Efficacy | 30 | 1 |
| Voltaren Gel (diclofenac sodium) | 31 | 1 |
| Overview | 31 | 1 |
| Mechanism of Action | 31 | 1 |
| Efficacy | 31 | 1 |
| Safety | 31 | 1 |
| Annual Cost of Therapy | 32 | 1 |
| Treatment Usage Patterns | 33 | 1 |
| Prevalence Population | 34 | 1 |
| Diagnosed Population | 34 | 1 |
| Prescription Population | 34 | 1 |
| Drivers and Restraints of the Pain Management Therapeutics Market | 35 | 1 |
| Drivers | 35 | 1 |
| Increasing Aging Population | 35 | 1 |
| Approval of New Products | 35 | 1 |
| Increased Awareness of Pain Indications | 35 | 1 |
| Active R&D Pipeline | 36 | 1 |
| Restraints | 36 | 1 |
| Pain Medications, Particularly Opioids, are Associated with Several Side-effects | 36 | 1 |
| Subjective Nature of Pain Diagnosis Leads to Low Prescription Rates | 36 | 1 |
| Availability of Generics | 36 | 1 |
| Pain Management Therapeutics Market to 2019 - Therapeutic Landscape | 37 | 67 |
| Pain Management Therapeutics Market for Fibromyalgia | 37 | 1 |
| Introduction | 37 | 1 |
| Revenue | 37 | 2 |
| Annual Cost of Therapy | 39 | 1 |
| Treatment Flow Algorithm | 40 | 1 |
| Treatment Usage Pattern | 41 | 1 |
| Prevalence Population | 42 | 1 |
| Diagnosed Population | 42 | 1 |
| Prescription Population | 42 | 1 |
| Geographical Segmentation | 43 | 1 |
| Drivers and Restraints for the Fibromyalgia Market | 44 | 1 |
| Drivers | 45 | 1 |
| Increasing Ageing Population | 45 | 1 |
| More Awareness and Better Diagnosis | 45 | 1 |
| Approval of Drugs for Fibromyalgia | 45 | 1 |
| Substantial Unmet Need Increases the R&D activity | 45 | 1 |
| Restraints for the Fibromyalgia Pain Relief Market | 45 | 1 |
| Inadequate Knowledge of Disease Progression | 45 | 1 |
| Adverse Effects of Medications | 45 | 1 |
| Pain Management Therapeutics for Neuropathic Pain | 46 | 1 |
| Introduction | 46 | 1 |
| Revenue | 46 | 2 |
| Annual Cost of Therapy | 48 | 1 |
| Treatment Flow Algorithm | 49 | 1 |
| Treatment Usage Pattern | 50 | 1 |
| Prevalence Population | 51 | 1 |
| Diagnosed Population | 51 | 1 |
| Prescription Population | 51 | 1 |
| Geographical Segmentation | 52 | 1 |
| Drivers and Restraints for the Neuropathic Pain Market | 53 | 1 |
| Drivers | 53 | 1 |
| Increasing Prevalence of Diseases such as Diabetes and HIV | 53 | 1 |
| Active Treatment-seeking Behavior | 53 | 1 |
| Increased Uptake of Approved Drugs | 53 | 1 |
| Restraints | 54 | 1 |
| Inaccuracy of Diagnostic Tools | 54 | 1 |
| Pain Management Therapeutics Market for Migraine | 55 | 1 |
| Introduction | 55 | 1 |
| Revenue | 55 | 2 |
| Annual Cost of Therapy | 57 | 1 |
| Treatment Flow Algorithm | 58 | 1 |
| Treatment Usage Pattern | 59 | 1 |
| Prevalence Population | 60 | 1 |
| Diagnosed Population | 60 | 1 |
| Prescription Population | 60 | 1 |
| Geographical Segmentation | 61 | 1 |
| Drivers and Restraints for the Migraine Market | 62 | 1 |
| Drivers | 62 | 1 |
| Increasing Awareness | 62 | 1 |
| Restraints | 62 | 1 |
| Patent Expiries of Major Drugs | 62 | 1 |
| Low Diagnosis Rate | 62 | 1 |
| Alternative Medicine and Self-Care Techniques | 62 | 1 |
| Pain Management Therapeutics Market for Cancer Pain | 63 | 1 |
| Introduction | 63 | 1 |
| Non-opioid Analgesics for Cancer Pain Management | 63 | 1 |
| Opioid Drugs: The Mainstay of Cancer Pain Management | 63 | 1 |
| Adjuvant Drugs | 63 | 1 |
| Revenue | 64 | 1 |
| Annual Cost of Therapy | 65 | 1 |
| Treatment Flow Algorithm | 66 | 1 |
| Treatment Usage Pattern | 67 | 1 |
| Prevalence Population | 68 | 1 |
| Diagnosed Population | 68 | 1 |
| Prescription Population | 68 | 1 |
| Geographical Segmentation | 69 | 1 |
| Drivers and Restraints for the Cancer Pain Market | 70 | 1 |
| Drivers | 70 | 1 |
| Increasing Incidence of Cancer | 70 | 1 |
| New Modes of Opioid Delivery | 70 | 1 |
| Unmet Need Due to Lack of Novel Modes of Action | 70 | 1 |
| Restraints | 71 | 1 |
| Risk of Addiction Reduces Prescription Rate | 71 | 1 |
| Fear that Treatment for Pain will Interfere in Cancer Treatment | 71 | 1 |
| Excessive State Regulation of Analgesics | 71 | 1 |
| Pain Management Therapeutics Market for Osteoarthritis Pain | 72 | 1 |
| Introduction | 72 | 1 |
| Revenue | 72 | 2 |
| Annual Cost of Therapy | 74 | 1 |
| Treatment Flow Algorithm | 75 | 1 |
| Treatment Usage Pattern | 76 | 1 |
| Prevalence Population | 77 | 1 |
| Diagnosed Population | 77 | 1 |
| Prescription Population | 77 | 1 |
| Geographical Segmentation | 78 | 1 |
| Drivers and Restraints for the Osteoarthritis Pain Market | 79 | 1 |
| Drivers | 79 | 1 |
| Increasing Ageing Population | 79 | 1 |
| Increase in Lifestyle-related Disorders | 79 | 1 |
| Restraints | 79 | 1 |
| Several Adverse Effects of Opioids | 79 | 1 |
| Low Treatment Seeking and Diagnosis Rates | 79 | 1 |
| Pain Management Therapeutics Market for Rheumatoid Arthritis Pain | 80 | 1 |
| Introduction | 80 | 1 |
| Revenue | 80 | 2 |
| Annual Cost of Therapy | 82 | 1 |
| Treatment Flow Algorithm | 83 | 1 |
| Treatment Usage Pattern | 84 | 1 |
| Prevalence Population | 85 | 1 |
| Diagnosed Population | 85 | 1 |
| Prescription Population | 85 | 1 |
| Geographical Segmentation | 86 | 1 |
| Drivers and Restraints for the Rheumatoid Arthritis Market | 87 | 1 |
| Drivers | 87 | 1 |
| Better Understanding of Disease through Biomarkers | 87 | 1 |
| Restraints | 87 | 1 |
| Inadequate Knowledge of Disease Symptoms among Patients | 87 | 1 |
| Several Adverse Effects of Drugs | 87 | 1 |
| Pain Management Therapeutics Market for Low Back Pain | 88 | 1 |
| Introduction | 88 | 1 |
| Revenue | 88 | 2 |
| Annual Cost of Therapy | 90 | 1 |
| Treatment Flow Algorithm | 91 | 1 |
| Treatment Usage Pattern | 92 | 1 |
| Prevalence Population | 93 | 1 |
| Diagnosed Population | 93 | 1 |
| Prescription Population | 93 | 1 |
| Geographical Segmentation | 94 | 1 |
| Drivers and Restraints for the Low Back Pain Market | 95 | 1 |
| Drivers | 95 | 1 |
| Increasing Aging Population | 95 | 1 |
| Sedentary Lifestyle | 95 | 1 |
| Restraints | 95 | 1 |
| Self-care Regimen and Low Prescription of Opioids | 95 | 1 |
| Pain Management Therapeutics Market for Post-operative Pain | 96 | 1 |
| Introduction | 96 | 1 |
| Revenue | 97 | 1 |
| Annual Cost of Therapy | 98 | 1 |
| Treatment Flow Algorithm | 99 | 1 |
| Treatment Usage Pattern | 100 | 1 |
| Prevalence Population | 101 | 1 |
| Diagnosed Population | 101 | 1 |
| Prescription Population | 101 | 1 |
| Geographical Segmentation | 102 | 1 |
| Drivers and Restraints for the Post-operative Pain Market | 103 | 1 |
| Drivers | 103 | 1 |
| Substantial Unmet Need | 103 | 1 |
| Convenient Titration of Pain Medications | 103 | 1 |
| Restraints | 103 | 1 |
| Growth of Minimally Invasive Surgical Procedures | 103 | 1 |
| Peri-operative Side Effects of Medications | 103 | 1 |
| Pain Management Therapeutics Market to 2019 - Geographical Landscape | 104 | 13 |
| The US | 105 | 1 |
| Revenue | 105 | 1 |
| Annual Cost of Therapy | 106 | 1 |
| Treatment Usage Pattern | 107 | 1 |
| Prevalence Population | 108 | 1 |
| Diagnosed Population | 108 | 1 |
| Prescription Population | 108 | 1 |
| Top Five European Countries | 109 | 1 |
| Revenue | 109 | 1 |
| Annual Cost of Therapy | 110 | 1 |
| Treatment Usage Pattern | 111 | 1 |
| Prevalence Population | 112 | 1 |
| Diagnosed Population | 112 | 1 |
| Prescription Population | 112 | 1 |
| Japan | 113 | 1 |
| Revenue | 113 | 1 |
| Annual Cost of Therapy | 114 | 1 |
| Treatment Usage Pattern | 115 | 1 |
| Prevalence Population | 116 | 1 |
| Diagnosed Population | 116 | 1 |
| Prescription Population | 116 | 1 |
| Pain Management Therapeutics Market to 2019 - Asia-Pacific and China | 117 | 17 |
| India | 117 | 1 |
| Regulatory Landscape | 117 | 2 |
| Effect of Patent Laws on Pharmaceutical Production in India | 119 | 1 |
| Patent Act 2005 First Step towards Improving IP Protection | 119 | 1 |
| IPR Enforcement Rule, 2007 | 119 | 1 |
